Charles River links with Distributed Bio to advance antibody discovery platform

monoclonal antibodies
Charles River has inked a partnership deal with Distributed Bio for access to antibody libraries and integrated antibody optimization technologies. (Novasep)

Charles River has inked a partnership deal with Distributed Bio that will give the CRO’s clients access to antibody libraries and integrated antibody optimization technologies.

Under the agreement, the two companies aim to create an end-to-end platform for therapeutic antibody discovery and development, they said.

San Francisco-based Distributed Bio provides computationally optimized libraries that can generate more than 5,000 unique hits against every antigen tested. Its platform can speed the discovery process to 3 to 4 months, it said.

Training Course

BioBasics: Biotech For The Non-Scientist

BioBasics: Biotech for the Non-Scientist is a two-day course for those who want to better understand the science driving the industry. The course starts with basic scientific concepts and quickly delves into the causes of genetic and infectious disease and the therapeutic strategies used to mitigate disease. The latest innovations in immunotherapies, gene therapy, checkpoint inhibitors, CAR-T and more are explained.

“Distributed Bio’s technology, coupled with Charles River’s deep scientific strength in drug discovery and early-stage development, ensure that our portfolio is truly next generation,” Birgit Girshick, Charles River’s EVP of Discovery and Safety, said in a statement. “This combination provides our clients with Distributed Bio’s ability to discover new antibodies, then proceed seamlessly from hit to clinical candidate faster than before.”

Earlier this year, in two separate agreements, Pfizer and Boehringer Ingelheim signed agreements for drug discovery using Distributed Bio’s library Super Human 2.0.

Suggested Articles reeled in $5 million in series A funding that it plans to use to accelerate lab deployment and expand other features.

Gottlieb challenged industry and academia to invest in new approaches and realign incentives to make clinical research more agile and effective.

Chinese biotech HitGen has inked a collaboration deal with India’s Sun Pharma Advanced Research arm to identify novel small molecule leads.